Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity
about
Cross talk of tyrosine kinases with the DNA damage signaling pathwaysTherapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancerGenome stability pathways in head and neck cancersDownregulation of Annexin A1 is correlated with radioresistance in nasopharyngeal carcinoma.Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization.Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib.Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerC-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expressionTumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidencePreclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.Rad51 in regulating the radiosensitivity of non-small cell lung cancer with different epidermal growth factor receptor mutation status.Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.Caffeic Acid Phenethyl Ester Increases Radiosensitivity of Estrogen Receptor-Positive and -Negative Breast Cancer Cells by Prolonging Radiation-Induced DNA Damage.Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cellsErlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical resultsEGFR inhibition in non-small cell lung cancer: current evidence and future directionsReceptor signaling as a regulatory mechanism of DNA repair.The role of apoptosis in radiation oncology.First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Clinical study on gefitinib combined with γ-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085).Modulating the tumor microenvironment to increase radiation responsiveness.A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancerBRCA1 16 years later: DNA damage-induced BRCA1 shuttling.Reversion of the ErbB malignant phenotype and the DNA damage response.H2AX a promising biomarker for lung cancer: a review.Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase.From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.[Epidermal growth factor receptor mutations and radiotherapy in non-small cell lung cancer].
P2860
Q26778614-2233E0AF-6A79-468E-B9C6-84BA21C5ED7FQ27004357-23925D09-195E-4714-BA79-BC6C9E8976A7Q28391355-AB83FD3D-D072-446F-977B-D5E01B87C2B4Q32183044-5C151542-3418-40D7-9A74-E7E87FAB49F1Q33831950-15B59D67-A556-4933-9CD6-88D0FF9F40A4Q34114278-61982E9E-0200-455E-9C1D-FEA466388143Q34970294-9D411EF3-CDAE-4C73-A8F3-ABEE39D0C421Q34985788-4F6B1400-B084-425E-9AD3-0DA05FE132AEQ35036774-70E0756A-614E-4298-8D40-ACAF71C09C8DQ35584972-A223C18D-B26E-4FD2-8A66-1805566BAD8FQ35608002-31644950-B796-4B4C-BFD9-42F9BA3589EEQ36101108-E339391F-C91E-4432-AF5B-7DD5F2CA4212Q36244267-306382AB-D7BC-4B9B-917A-AC7724554A52Q36250585-2E5B0B33-5783-4431-8FE4-9830120AD1B1Q36388217-958320AB-D39F-4E46-BAF7-C48D0F6682D5Q36477745-A13C480E-7E11-4D91-8AFA-EF9E94E052D5Q36500914-45E8B73D-B9CA-4F6B-8331-7707696AD734Q36768974-74E217CF-2DFD-4499-A49B-0EA4BB749BF8Q36896122-DDFD12BF-2201-43F6-98FD-2F35D90F27F3Q36982835-0CACDF43-E4D2-488D-8F3C-471BB8779580Q37105715-7E2F61DA-4F7A-4B01-A161-F2BC26E31292Q37180302-62A47112-424D-4950-8B5D-BFAACC56EC92Q37368256-2ED65F33-7B13-45A3-AA9A-79CA51130506Q37413111-90B5B339-E335-4BED-8263-6C1B8AFC81DBQ37544367-307752DC-EAE9-4A27-8AD4-0B1CFD1D804AQ37560695-A74F62AD-1A6C-4048-8315-E97498C555CCQ37613364-BE37191C-4A11-459F-AC01-FC072D1540A5Q37716645-E9D6550E-F437-4EE9-B5A0-53400BD2F328Q37770591-DD73882A-44A1-423B-B4AD-B2305D70521DQ38047648-AE323E9F-3D5A-446B-8574-F4A1BDBBB060Q38155902-1DFB4D4F-374E-4EB1-8E19-4C69BB67D6F4Q38171330-D610918F-64CC-4976-827C-9EEEF26E4FC1Q38807186-54774731-A412-425B-A86E-A7BABB467711Q38869420-3AC0AD19-BB2C-4E84-BC6E-194B72689979Q38973520-37FA695B-4297-48C0-AFE4-6377BAA286BBQ39041541-4CF8257B-D227-471A-A81D-8A3AF10CC7C8Q39660788-3172C772-C264-4482-BCF6-DB4071CAA149Q39696362-A0E459E7-F18E-45E7-AB1A-1804FAA30F6AQ41339882-BB3A9540-177F-454F-B684-D6D3C2949318Q44478432-2C6B3056-2D95-4A21-953A-1FBCE5216EB0
P2860
Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@ast
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@en
type
label
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@ast
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@en
prefLabel
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@ast
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@en
P2093
P2860
P1476
Gefitinib radiosensitizes non- ...... g cellular DNA repair capacity
@en
P2093
Anupama Munshi
Colin Brooks
Marvette L Hobbs
Raymond E Meyn
Toshimitsu Tanaka
P2860
P304
P356
10.1158/1078-0432.CCR-07-1606
P407
P577
2008-02-01T00:00:00Z